Impact of Anticholinergic Medication on Salivary Function; Exploring Potential Genetic Markers for Dry Mouth
抗胆碱能药物对唾液腺功能的影响;
基本信息
- 批准号:10283183
- 负责人:
- 金额:$ 12.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-13 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAdverse effectsAffectAffinityAgeAllelesAnti-CholinergicsAntidepressive AgentsAppointmentAustraliaBiological AssayBloodCYP2C19 geneCYP2D6 geneChemosensitizationCholinergic ReceptorsClinicalClinical ResearchClinical TreatmentClinical TrialsCytochrome P450CytochromesDNADataDeglutitionDeliriumDementiaDentalDental cariesDevelopmentDrug PrescriptionsDrynessDyskinetic syndromeElderlyEnzymesEquipment and supply inventoriesEuropeFeelingFrequenciesFutureGeneticGenetic MarkersGenetic PolymorphismGenetic VariationGoalsGoldHealthImpaired cognitionImpairmentIndividual DifferencesInfectionIntakeInvestigationLeadLiverMasticationMeasurementMeasuresMemory impairmentMetabolicMinor salivary gland structureMonitorMucous MembraneMuscarinic Acetylcholine ReceptorMuscarinicsNeurologicNorth AmericaOralOral Health Impact ProfileOral cavityOral healthOrganOutcomeParasympathetic Nervous SystemPatientsPeripheralPharmaceutical PreparationsPharmacogeneticsPhenotypePolypharmacyPopulationPredispositionPrevalencePreventionPropertyProphylactic treatmentProspective cohort studyPsychosesQuality of lifeQuestionnairesRandomizedReportingResearchRiskRoleSalivaSalivarySalivary GlandsSerumSeveritiesSignal TransductionSpasmolyticsSurveysSymptomsTestingTooth LossToxic effectUpper Respiratory InfectionsUpper respiratory tractVariantVisitXerostomiaage effectaging populationbasecholinergicclinically relevantcurative treatmentsdesigndouble-blind placebo controlled trialdrug metabolismearly screeninggenetic variantgenotyped patientshigh riskinter-individual variationmiddle ageneuroregulationneurotransmissionpersonalized medicinepoint of carepoint of care testingprospectivereceptorrecruitrisk predictionsaliva secretionscreeningside effectsoft tissuetreatment strategyurinary
项目摘要
The growing medication use in all ages led to the fact that 20% of the US adult population take five or more
drugs (polypharmacy). Over 500 medications commonly prescribed in polypharmacy (e.g., antidepressants,
urinary antispasmodics, and psycholeptics) possess anticholinergic (AC) properties blocking the muscarinic
signaling of neural regulation. Due to the scattered distribution of muscarinic receptors in the body, AC
medications have a wide range of side effects. Besides the most severe central toxicity of cognitive impairment,
dyskinesia, and psychosis, which can lead to delirium, the most frequent peripheral side effect is dry mouth. Dry
mouth is characterized by reduced saliva secretion (hyposalivation), impaired quality of life by causing chewing
or swallowing problems, complaints of oral dryness (xerostomia), speaking difficulties, mucosal changes,
increased rate of dental caries, and tooth loss. Dry mouth causes increased susceptibility to bacterial colonization
and infections in the oral cavity and the upper respiratory tract. However, no data are available on predicting
medication-induced dry mouth severity or determining the AC burden from these medications among dental
patients. There is a significant research gap in identifying high-risk xerostomia patients in the middle-aged
population before reaching older ages when damage to oral health is irreversible. We designed a prospective
cohort study with two aims for addressing these questions. In Aim 1., we will evaluate the correlation between
AC burden and dry mouth outcomes, including the flow rates of the minor salivary glands (SG) in 90 middle-
aged patients (45-64 years). We will determine whether high AC burden, quantified by the AC drug score (ADS)
and serum AC activity (SAA) in blood, is associated with more severe dry mouth symptoms, measured at
baseline and follow-ups for two years. We will assess dry mouth using saliva flow rates (unstimulated whole
saliva and minor SGs) and oral health measures associated with dry mouth, including xerostomia, dental caries,
and oral health impact profile. In this aim, we will examine the feasibility of minor SG flow screening as a point-
of-care test for dry mouth. In Aim 2., we will explore whether CYP450 genetic polymorphisms predict dry mouth
severity. Recent studies reported an increased prevalence of AC side effects in patients with inactive genetic
variants of liver cytochrome P450 enzymes responsible for the metabolic clearance of AC drugs. We will analyze
DNA from patients’ blood for the genetic variations of CYP2D6 and CYP2C19 enzymes and compare oral health
outcomes associated with dry mouth between poor and normo-metabolizing phenotypes. We propose to study
whether dry-mouth pharmacogenetics provides evidence for inter-individual variability in oral health outcomes to
identify patients with predictable severity of AC medication-induced dry mouth. The overarching goal of our
explorative study is to establish clinically relevant associations between AC burden and oral health outcomes,
which can support future investigations of potential causal relationships and risk calculations for dry mouth
development.
所有年龄段的药物使用不断增加,导致20%的美国成年人服用五种或更多种药物。
多药疗法(Polypharmacy)超过500种药物通常在多药治疗中处方(例如,抗抑郁药,
尿解痉剂和精神抑制剂)具有抗胆碱能(AC)特性,
神经调节的信号。由于毒蕈碱受体在体内的分散分布,AC
药物有很多副作用。除了最严重的中枢毒性认知障碍,
运动障碍和精神病,这可能导致谵妄,最常见的外周副作用是口干。干
口腔的特征是唾液分泌减少(少涎),咀嚼导致生活质量受损
或吞咽问题,口腔干燥(口干症),说话困难,粘膜变化,
龋齿和牙齿脱落率增加。口干导致对细菌定植的易感性增加
以及口腔和上呼吸道感染。然而,没有数据可以预测
药物引起的口干严重程度或确定牙科患者中这些药物的AC负担
患者在识别中年高危口腔干燥症患者方面存在显著的研究空白
当口腔健康受到不可逆转的损害时,老年人的口腔健康将受到影响。我们设计了一个
队列研究有两个目的来解决这些问题。在目标1中,我们将评估
AC负担和口干结果,包括90名中老年人小唾液腺(SG)的流速
老年患者(45-64岁)。我们将确定高AC负荷(通过AC药物评分(ADS)量化)
和血液中的血清AC活性(SAA),与更严重的口干症状相关,
基线和两年的随访。我们将使用唾液流速(未刺激的整体)评估口干
唾液和次要SG)和与口干相关的口腔健康测量,包括口腔干燥,龋齿,
和口腔健康影响概况。为此,我们将研究小SG流量筛选的可行性,
口腔干燥的护理测试。在目标2中,我们将探讨CYP 450基因多态性是否能预测口干
严重性。最近的研究报告了AC副作用在非活动性遗传病患者中的患病率增加。
负责AC药物代谢清除的肝细胞色素P450酶的变体。我们将分析
来自患者血液的DNA用于CYP 2D 6和CYP 2C 19酶的遗传变异并比较口腔健康
结果与口干之间的穷人和正常代谢表型。我们建议研究
口干药物遗传学是否为口腔健康结果的个体间差异提供了证据,
确定具有可预测的AC药物诱导的口干严重程度的患者。我们的首要目标是
探索性研究旨在建立AC负荷与口腔健康结果之间的临床相关性,
这可以支持未来对口干的潜在因果关系和风险计算的调查
发展
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Szilvia Arany其他文献
Szilvia Arany的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Szilvia Arany', 18)}}的其他基金
Impact of Anticholinergic Medication on Salivary Function; Exploring Potential Genetic Markers for Dry Mouth
抗胆碱能药物对唾液腺功能的影响;
- 批准号:
10450110 - 财政年份:2021
- 资助金额:
$ 12.76万 - 项目类别:
Impact of Anticholinergic Medication on Salivary Function; Exploring Potential Genetic Markers for Dry Mouth
抗胆碱能药物对唾液腺功能的影响;
- 批准号:
10650163 - 财政年份:2021
- 资助金额:
$ 12.76万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 12.76万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 12.76万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 12.76万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 12.76万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 12.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 12.76万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 12.76万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 12.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 12.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 12.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)